Shilpa Medicare receives Europe GMP Certification for Hyderabad facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-12-22 10:01 GMT | Update On 2024-12-22 10:01 GMT
MoS Health Justifies Yearly Inspection of Medical Colleges by NMC
Karnataka: Shilpa Medicare has received the Good Manufacturing Practice (GMP) Certification after the successful closure of the EMA, Europe inspection at Unit 7, Nacharam, Hyderabad, Telangana, India.
The inspection was conducted from 24th to 26th September 2024.
"This is to inform you that the Shilpa Medicare Limited, Unit 7, Nacharam, Hyderabad, Telangana, India had completed an inspection from EMA, Europe from 24th to 26th September 2024," the Company stated.
Shilpa Medicare Limited, Unit VII, has an Analytical Services Division (QC) and a Bio Analytical Department. Both laboratories are approved by USFDA. The Bio-Analytical Laboratory is already approved by EMA, Europe.
This inspection was a Europe inspection for the QC laboratory of Unit VII. This Laboratory is involved in testing drug substances, raw materials, packing materials and finished products. It is also engaged in other analytical activities like analytical method validations, method transfers and other miscellaneous analytical studies. The laboratory has been testing samples for final release into US, EU and other markets.
Medical Dialogues team had earlier reported that the Company's Joint Venture Oncosol (50:50 JV with Liqmeds Lifecare Limited, a Zydus group company and Koana Healthcare Limited, Shilpa Medicare group company) along with its partner Shorla Oncology had received the approval from the US Food and Drug Administration (USFDA) for IMKELDI (imatinib oral solution), a oral liquid form of imatinib to treat certain forms of leukemia and other cancers.
Read also: Shilpa Medicare-Zydus JV gets USFDA nod for Imkeldi for certain forms of leukemia, other cancers
Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.